Childhood myopia is a global epidemic — and Egypt is not immune. Clinit's myopia management module tracks axial length progression, intervention outcomes, and recall compliance for every at-risk child.
The Myopia Epidemic
The WHO projects that by 2050, half the world's population will be myopic. In urban Egypt — with high screen time, reduced outdoor activity, and early school pressure — the paediatric myopia rate is accelerating. For optical clinics, this is both a clinical responsibility and a significant practice builder.
Why Tracking Matters More Than Prescribing
A spherical equivalent refraction of −1.50 D at age 8 is not the same clinical situation as −1.50 D at age 12. The first child has years of potential progression ahead; the second is likely stabilising. Without axial length measurement and trend tracking, every new prescription is a reactive response to a problem that could have been anticipated and slowed.
What Clinit's Myopia Module Tracks
Per visit:
- Date, age, visual acuity (corrected and uncorrected)
- Cycloplegic refraction — sphere, cylinder, axis, spherical equivalent
- Axial length (AL) — entered from IOLMaster or Lenstar
- Intraocular pressure (IOP) if measured
Trend charts:
- SE progression curve overlaid against population percentile bands (Brien Holden Vision Institute data)
- Axial length growth curve — the most sensitive indicator of progression
- AI flags any child whose AL growth exceeds 0.3 mm/year — the threshold associated with high myopia risk
Intervention Tracking
When an intervention is started — orthokeratology lenses, low-concentration atropine (0.01%–0.05%), soft multifocal contact lenses, or spectacle lenses with peripheral defocus — the module records the start date, product/concentration, and the AL at initiation. The pre- and post-intervention growth rates are compared automatically.
Parent Communication
Parents receive a plain-language summary via the patient portal after each visit: "Your child's axial length grew 0.15 mm since the last visit — within the target range. Continue current treatment."
